Antibody Drug Conjugates (ADCs) Drug Sales, Pipeline Analysis & Market Expected to Exceed USD 19.8 Billion by 2032 with 10.67% CAGR
The Antibody Drug Conjugates Drug Sales, Pipeline Analysis & Market is primarily driven by the increasing prevalence of cancer across global populations. As cancer continues to be one of the leading causes of mortality worldwide, pharmaceutical companies are intensifying their investments in next-generation therapies that can deliver targeted action with minimal off-target toxicity. ADCs offer a compelling … Read more